Our Take
The growth story is real, but regulatory gaps and unproven claims remain structural headwinds that policy alone won't fix.
Why it matters
India's shift from treatment to prevention is reshaping where health spending flows. For investors and operators, the market window is open but crowded with products lacking scientific validation.
Do this week
Manufacturers: audit your product claims against FSSAI guidelines this quarter so you don't face compliance friction when the regulator tightens enforcement.
Market size and growth trajectory
India's nutraceutical market is forecast to grow from $29–30 billion in 2024 to $55–57 billion by 2030, according to a CareEdge report. The sector is expected to reach $37–38 billion by 2026, with a compound annual growth rate of 10.5% (per CareEdge). The expansion is being driven by rising health consciousness, increased prevalence of lifestyle diseases, and nutritional deficiencies across the population.
Growth is being supported by three structural factors. E-commerce and digital health platforms are expanding distribution beyond traditional retail. Government support from the Food Safety and Standards Authority of India (FSSAI) and the Ministry of Food Processing Industries (MoFPI) is improving regulatory standardisation and quality control. India's agricultural base provides a cost advantage in sourcing raw materials for nutraceutical formulations.
Prevention over treatment is reshaping health spending
India's healthcare ecosystem is undergoing a documented shift away from illness management toward prevention, wellness, and long-term health management. Nutraceuticals, which combine nutritional and pharmaceutical benefits, sit at the centre of this transition. For consumer health companies and investors, this represents a structural reallocation of spending within the healthcare budget.
However, three risks constrain near-term growth. Evolving regulations create compliance uncertainty for smaller manufacturers. Misleading product claims remain endemic, with limited scientific validation for many functional foods and dietary supplements. Consumer awareness gaps mean many buyers cannot distinguish between legitimate products and overstated offerings. Policy support is helping, but does not resolve the deeper problem of unproven efficacy claims.
What to do now
If you operate in nutraceuticals or supply the sector, assume regulatory scrutiny will tighten as the market grows and foreign capital enters. Document your claims against peer-reviewed evidence, not marketing convenience. The companies that build trust early will capture disproportionate share as consumer sophistication rises. If you're evaluating the sector for investment or partnership, treat scientific validation as a moat, not an afterthought.